FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer

Biomarkers to identify patients without benefit from adding everolimus to endocrine treatment in metastatic breast cancer (MBC) are needed. We report the results of the Pearl trial conducted in five Belgian centers assessing (18)F-FDG-PET/CT non-response (n = 45) and ctDNA detection (n = 46) after 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Gombos, Andrea, Venet, David, Ameye, Lieveke, Vuylsteke, Peter, Neven, Patrick, Richard, Vincent, Duhoux, Francois P., Laes, Jean-Francois, Rothe, Françoise, Sotiriou, Christos, Paesmans, Marianne, Awada, Ahmad, Guiot, Thomas, Flamen, Patrick, Piccart-Gebhart, Martine, Ignatiadis, Michail, Gebhart, Géraldine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455671/
https://www.ncbi.nlm.nih.gov/pubmed/34548493
http://dx.doi.org/10.1038/s41523-021-00331-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455671/
https://www.ncbi.nlm.nih.gov/pubmed/34548493
http://dx.doi.org/10.1038/s41523-021-00331-8

Ejemplares similares